Evidence map›Paper›PMID 36568691›Full record

ArticlePulmonary circulation2022

Socioeconomically disadvantaged veterans experience treatment delays for pulmonary arterial hypertension.

Kari R Gillmeyer, Seppo T Rinne, Shirley X Qian, Bradley A Maron, Shelsey W Johnson, Elizabeth S Klings, Renda S Wiener

Open access · goldAbstract read
In one paragraph

Article in Pulmonary circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Pulmonary Hypertension Care Delivery in the United States: Is It Time to Get with the Guidelines?American journal of respiratory and critical care medicine · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kari R GillmeyerThe Pulmonary Center Boston University School of Medicine Boston Massachusetts USA.ORCID https://orcid.org/0000-0002-5333-259X
Seppo T RinneThe Pulmonary Center Boston University School of Medicine Boston Massachusetts USA.ORCID https://orcid.org/0000-0002-8662-1224
Shirley X QianCenter for Healthcare Organization & Implementation Research VA Bedford Healthcare System and VA Boston Healthcare System Bedford and Boston Massachusetts USA.
Bradley A MaronDepartment of Cardiology VA Boston Healthcare System Boston Massachusetts USA.ORCID 0000-0002-6784-764X
Shelsey W JohnsonThe Pulmonary Center Boston University School of Medicine Boston Massachusetts USA.ORCID https://orcid.org/0000-0002-6297-6389
Elizabeth S KlingsThe Pulmonary Center Boston University School of Medicine Boston Massachusetts USA.ORCID https://orcid.org/0000-0003-4879-720X
Renda S WienerThe Pulmonary Center Boston University School of Medicine Boston Massachusetts USA.ORCID https://orcid.org/0000-0001-7712-2135
Boston University · USBrigham and Women's Hospital · USVA Boston Healthcare System · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
BIOLOGY OF THE LUNG--MULTIDISCIPLINARY PROGRAMT32HL007035 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton, JOSEPH P MIZGERD · 1985 to 2026
$24.3M
Boston Biomedical Innovation CenterU54HL119145 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLAN, DAVID E., LOSCALZO, JOSEPH · 2013 to 2021
$18.8M
Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertensionR01HL139613 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Sirano Dhe-Paganon, Bradley Maron · 2018 to 2026
$4.1M
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertensionR01HL155096 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARON, BRADLEY · 2021 to 2024
$1.6M
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)UG3HL143192 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLADWIN, MARK T, TRIULZI, DARRELL J · 2019 to 2019
$1.5M
Network medicine, risk stratification, and pulmonary hypertensionR21HL145420 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARON, BRADLEY · 2019 to 2020
$287k
Determining disparities in treatment of pulmonary arterial hypertension nationallyF32HL149236 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GILLMEYER, KARI · 2019 to 2020
$157k
NCATS NIH HHS UL1 TR001430NHLBI NIH HHS F32 HL149236NHLBI NIH HHS R01 HL139613NHLBI NIH HHS R01 HL155096NHLBI NIH HHS R21 HL145420NHLBI NIH HHS T32 HL007035NHLBI NIH HHS U54 HL119145NHLBI NIH HHS UG3 HL143192
6 · The paper itself

Abstract

Prompt initiation of therapy after pulmonary arterial hypertension (PAH) diagnosis is critical to improve outcomes; yet delays in PAH treatment are common. Prior research demonstrates that individuals with PAH belonging to socially disadvantaged groups experience worse clinical outcomes. Whether these poor outcomes are mediated by delays in care or other factors is incompletely understood. We sought to examine the association between race/ethnicity and socioeconomic status and time-to-PAH treatment. We conducted a retrospective cohort study of Veterans diagnosed with incident PAH between 2006 and 2019 and treated with PAH therapy. Our outcome was time-to-PAH treatment. Our primary exposures were race/ethnicity, annual household income, health insurance status, education, and housing insecurity. We calculated time-to-treatment using multivariable mixed-effects Cox proportional hazard models. Of 1827 Veterans with PAH, 27% were Black, 4% were Hispanic, 22.1% had an income < $20,000, 53.3% lacked non-VA insurance, 25.5% had <high school education, and 3.9% had housing insecurity. Median time-to-treatment was 114 days (interquartile range [IQR] 21-336). Our multivariable models demonstrated increased time-to-treatment among patients with lower household income (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.60-0.91 for < $20,000 vs. ≥ $100,000) and those without non-VA insurance (HR 0.90, 95% CI 0.82-1.00). Race/ethnicity, education, and housing insecurity were not associated with time-to-treatment. Veterans with PAH experienced substantial and potentially harmful treatment delays, with median time-to-treatment of 16 weeks after diagnosis. Those with lower income and those without non-VA health insurance experienced even greater treatment delays. Additional research is urgently needed to develop interventions to improve timely PAH treatment and mitigate economic disparities in treatment.

Indexed as

pulmonary arterial hypertensionracial, ethnic, or social disparities in lung disease and treatmentresearch design/program evaluation/statistical models

Identifiers

PMID36568691
PMCPMC9768567
OpenAlexW4311533500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.